Sign in
Enrolling by invitationPhase 1/2

Personalized gene-targeting drug for one person with Charcot-Marie-Tooth disease type 2D

Tests a custom antisense drug in one person with Charcot-Marie-Tooth disease type 2D.

Key facts

Who runs it
n-Lorem Foundation
Where
Houston, United StatesSee the site
Trial code
Registry title
Personalized Antisense Oligonucleotide for A Single Participant With GARS1 Gene Mutation Associated With Charcot-Marie-Tooth Disease Type 2D (CMT2D)
Status
Enrolling by invitation
Phase
Phase 1/2
People taking part
1 person, planned
Started
27 Oct 2025
Expected to end
Oct 2027
Type of study
Interventional
Treatments tested
  • nL-GARS1-001
Record updated
10 November 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for one single participant with Charcot-Marie-Tooth disease type 2D (CMT2D) caused by a change in the GARS1 gene. The participant gets a personal experimental drug called nL-GARS1-001.

Age
13 Years and older
Sex
Female
Disease stage
Charcot-Marie-Tooth disease type 2D (CMT2D) due to a harmful, new (de novo) deletion in GARS1.
Biomarker or test result
A GARS1 gene change confirmed by genetic testing.

Main reasons for not taking part

  • Any condition that, in the study doctor's opinion, would stop the participant from completing the study steps.
  • Not able to travel to the study site and attend follow-up visits.

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • Informed consent/assent provided by the participant (when appropriate), and/or the participant's parent(s) or legally authorized representative(s)
  • Ability to travel to the study site and adhere to study-related follow-up examinations and/or procedures and provide access to participant's medical records; Genetically confirmed GARS1 genetic variant

Who cannot take part

  • Participant has any condition that, in the opinion of the Site Investigator, would ultimately prevent the completion of study procedures

Where in United States

  • UTHealth HoustonHouston, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with Charcot-Marie-Tooth disease type 2D (CMT2D) due to a pathogenic, de novo deletion mutation in GARS1

The group in the trial

  • Open LabelTreatment being tested

    Treatment: nL-GARS1-001

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Open-label Single Center, Single Participant Study of an Experimental Antisense Oligonucleotide Treatment for Charcot-Marie-Tooth Type 2D Due to GARS1 Genetic Mutation
Plain-language title
Personalized gene-targeting drug for one person with Charcot-Marie-Tooth disease type 2DGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
10 November 2025